Oral Tonabersat Connexin-43 Modulator for Diabetic Macular Edema with Good Vision (DRCR Retina Network Protocol AN)

Le résumé fourni par la source

Objective Evaluate oral tonabersat, a connexin43 hemichannel modulator, on central subfield thickness (CST) in eyes with center-involved DME (CI-DME) and good vision. Design Phase 2 randomized, double-masked clinical trial. Participants 129 adults with CI-DME and visual acuity 20/32 or better, recruited from 24 sites in the US. Intervention Participants randomly assigned 1:1 to 80-mg tonabersat (N=64, [71 eyes]) or placebo (N=65, [73 eyes]) for 6 months. Main Outcome Measures Change in OCT CST. Results Overall, 37% of participants were female; mean age 63 years. In the tonabersat and placebo groups respectively, baseline mean CST was 359μm and 362μm;the mean (SD) change in CST from baseline to 6 months was -15 (55) μm and +5 (51) μm; (adjusted mean difference: -16 [95% CI, -34 to 2], P=0.08). A post-hoc analysis using last observation carried forward prior to any anti-VEGF treatment showed an adjusted mean difference: -21 [95% CI, -38 to -3], P=0.02. Among participants with thinner eyes at baseline (CST <75-μm above the threshold; tonabersat group (n=45) versus the placebo group (n=43)), the adjusted mean difference was -2 μm (95% CI, –26 to 22). For thicker eyes (CST ≥75-μm above the threshold; tonabersat group (n=20) versus the placebo group (n=24)), the mean difference was -51 μm (95% CI, –83 to –19). In the tonabersat and placebo groups respectively, the mean (SD) change in best-corrected VA from baseline to 6 months was 0.0 (5.7) letters and -0.4 (5.7) letters (adjusted mean difference: 0.82 [95% CI, -1.56 to 3.21], adjusted P=0.39). Dizziness was more common with tonabersat than placebo (27% vs 8%), headaches were more common with placebo (17% vs 6%), and drowsiness occurred at similar rates (11% in both groups). Conclusions In the primary analysis, there was no statistically significant improvement in CST at 6 months in the tonabersat versus placebo groups. However, a post-hoc analysis that limited anti-VEGF impact demonstrated statistically significant benefit in the tonabersat group. Aside from increased dizziness with tonabersat, consistent safety concerns were not identified. Given findings consistent with a potentially favorable biologic effect of tonabersat, further research into the role of the NLRP3 inflammasome in DME is warranted.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.